Multidrug-resistant tuberculosis (MDR-TB) is widespread globally with almost half a million cases documented in 2014. Although rare in European countries, the risks posed by the current migrant crisis makes MDR-TB an important and urgent public health priority. A study just published in Clinical Microbiology and Infection documents that the rate of infection with MDR-TB is higher among migrants than in the general population, particularly in those born outside Europe and in those forced to leave their home country as asylum seekers and refugees.
The data reviewed by Hargreaves, et al. shows that 100 percent of the MDR-TB cases diagnosed in Austria, The Netherlands and Norway occurred in migrants to those countries. A high proportion of MDR-TB cases were also apparent in migrants to other European states – 90 percent in the UK, 89 percent in France, 87 percent in Italy and 94 percent in Germany.
Migrants are at higher risk of contracting MDR-TB both in their country of origin, because of the breakdown of their own healthcare system, and after arriving in Europe, because of destitution, homelessness, overcrowding in refugee camps or incarceration. A significant proportion of MDR-TB cases in migrants result from reactivation of latent infection.
Screening, diagnosis and treatment is available for all forms of TB, including active MDR-TB. However, this is rarely accessed by migrants due to restrictions set by healthcare systems or to fear on the part of the migrants that becoming known to the authorities might result in deportation back to the violence they have fled.
“Although there is evidence that transmission of TB from migrants to the general population is low – it predominantly occurs between migrants – there is a risk of transmission for both migrants and the native population,” notes professor Jon S. Friedland of the International Health Unit, Infectious Diseases & Immunity, Imperial College London, UK, who is senior author of the study. “There is a human rights obligation to improve the diagnosis, treatment and prevention of MDR-TB in migrants.”
After analyzing the content of several studies on MDR-TB, the paper recommends a multi-faceted strategy to improve access to services, more consistent pan-European protocols for screening and treatment, and further research to document the level of MDR-TB infection in the European migrant population.
Detailed recommendations include:
- Changing healthcare policies so that there are fewer barriers to migrants with respect to TB screening, diagnosis and treatment. This would not be granting ‘favors’ to migrants; it would be a sound public health policy to reduce the risk of MDR-TB transmission to other migrants and the wider population.
- Providing better healthcare generally to migrant populations in individual host countries.
- Developing financial and social support mechanisms for migrants who are diagnosed with MDR-TB.
- Drawing up and adopting pan-European evidence-based guidelines for screening methods and how to implement them in the migrant populations.
- Research is also required to develop a reliable diagnostic test that can detect latent MDR-TB and to predict the risk of disease re-activation.
- More evidence that can be used to develop guidelines on how to manage MDR-TB more effectively in migrant populations across Europe is needed
Source: ESCMID
Show, Tell, Teach: Elevating EVS Training Through Cognitive Science and Performance Coaching
April 25th 2025Training EVS workers for hygiene excellence demands more than manuals—it requires active engagement, motor skills coaching, and teach-back techniques to reduce HAIs and improve patient outcomes.
The Rise of Disposable Products in Health Care Cleaning and Linens
April 25th 2025Health care-associated infections are driving a shift toward disposable microfiber cloths, mop pads, and curtains—offering infection prevention, regulatory compliance, and operational efficiency in one-time-use solutions.
Phage Therapy’s Future: Tackling Antimicrobial Resistance With Precision Viruses
April 24th 2025Bacteriophage therapy presents a promising alternative to antibiotics, especially as antimicrobial resistance continues to increase. Dr. Ran Nir-Paz discusses its potential, challenges, and future applications in this technology.